NCT00301574View on ClinicalTrials.gov

An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.

PHASE3CompletedINTERVENTIONAL
Enrollment

398

Participants

Timeline

Start Date

April 30, 2001

Study Completion Date

February 29, 2004

Conditions
Alzheimer Disease
Interventions
DRUG

galantamine

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT00301574 - An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease. | Biotech Hunter | Biotech Hunter